Overcoming the challenges of extra-hepatic targeting Although RNAi technology has demonstrated great promise in treating liver diseases, its application to extra-hepatic organs is still in its ...

2018 saw a breakthrough in the field of RNA interference (RNAi), when the US FDA approved the first drug using this gene-silencing mechanism. Five years and five more approved drugs later, RNAi ...

RNA interference – RNAi – functions specifically to silence, or deactivate, genes. Among other applications, it promises to be groundbreaking as a way to treat infections of bees by a commercially ...

Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, ...

Discover how RNA therapeutics are reshaping medicine, offering new treatments for previously undruggable targets.

Farmers looking to gain the upper hand over corn rootworm (CRW) pests have new tools to deploy in the field, thanks to Ribonucleic acid interference (RNAi) technology. RNAi works in CRW as it ...

Cardiovascular disease (CVD) is the leading cause of death globally, and combating this range of complex disorders presents numerous challenges. Scientists seek innovative approaches to address this ...

Alnylam’s RNAi technology could potentially mimic the naturally occurring loss of function genetic variation in HSD17B13 seen in people who are protected from NASH disease progression.

RNA technology-based therapeutics are a new and novel way to treat diseases. RNA medicines utilise biological processes to express proteins and create a therapeutic effect offering the potential ...

RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...

Once researchers begin wondering whether their government might pull the rug from under them, the damage is done ...